Caribou Biosciences is a leading clinical-stage CRISPR genome editing biotechnology company developing an internal pipeline of off-the-shelf, genome-edited CAR-T and natural killer (NK) cell therapies.
For more details on financing and valuation for Caribou Biosciences, register or login.
By registering, you agree to Forge’s Terms of Use. Already registered? Log in
CRBU
5.31 as of 3/31/23
To read this article and more news on Caribou Biosciences, register or login.
